9amHealth announced a $26 million Series B financing round led by Define Ventures, with participation from SemperVirens VC, Catalio Capital Management, and NewHealth Ventures. The company said the funding will support expansion of its AI-enabled virtual specialty care platform beyond cardiometabolic care into additional chronic conditions that collectively account for up to 70% of employer pharmacy spending.
Founded in 2021, 9amHealth partners with enterprise employers, health plans, and pharmacy benefit managers to provide care for individuals living with obesity, diabetes, hypertension, and dyslipidemia. The company’s care model combines clinical protocols, laboratory testing, medication management, and ongoing virtual care services.
According to the company, its platform has already generated more than $50 million in projected medical and pharmacy savings across two Fortune 100 employers while improving member engagement and clinical outcomes amid rising demand for GLP-1 therapies.
The company said it has already developed the clinical infrastructure, care delivery systems, and technology platform needed to manage more complex and higher-cost chronic conditions at scale. These conditions frequently require specialty medications, recurring interventions, and coordinated clinical care, making them among the largest contributors to employer healthcare spending.
9amHealth said its platform combines specialized clinical care with AI-enabled workflows and personalized member experiences to improve scalability and operational efficiency across chronic care management programs.
Members of the platform receive access to endocrinologists, obesity medicine specialists, clinical pharmacists, at-home laboratory testing, prescription medications, and lifestyle support services.
As part of the financing, Lynne O’Keefe will join the company’s board of directors.
9amHealth is also backed by investors including 7Wire Ventures and The Cigna Group Ventures.
KEY QUOTES:
“What makes this possible is our ability to combine specialized clinical care with AI-enabled clinical workflows and personalized member experiences that allow us to scale efficiently across complex chronic conditions. We’ve already proven this model in cardiometabolic care, and are now extending to a much broader set of high-cost needs.”
Frank Westermann, CEO And Co-Founder, 9amHealth
“We’re proud to partner with 9amHealth at this pivotal stage. They’ve demonstrated strong clinical outcomes and cost savings in one of the fastest-growing categories in healthcare. Their platform has the potential to transform how employers manage their most expensive populations.”
Lynne O’Keefe, Founder And Managing Partner, Define Ventures
